Hadassah

Life After Childhood Cancer: Hadassah Assesses Kids’ Self-Esteem

Wednesday, Dec 23 2015

An illustration of a healthy eye versus an eye with retinoblastoma.

“The cure cannot be limited to freedom from cancer, but must also afford childhood cancer survivors the same physical and psychological quality of life enjoyed by their healthy peers,” says Prof. Michael Weintraub, Director of the Hadassah Medical Center’s Department of Pediatric Hemato-Oncology.

Over 95 percent of children are cured of a malignant eye tumor called retinoblastoma (RB). But what quality of life do survivors of this childhood cancer have? This is a question that Hadassah is researching with the ultimate goal of designing an intervention program that will address the  deficits these children experience.

As Prof. Weintraub explains: The side effects of the various treatments may have psychological and social consequences-- impaired self-esteem and body image, as well as lower academic achievements. Hadassah is devoted to delineating those areas in which the quality of life for these cancer survivors has been compromised, either by the disease or treatment.

RB is a malignant eye tumor that occurs exclusively in infants and children. In some children, only one eye is affected; in others, both eyes have RB. Approximately 40% of the cases are hereditary. Typically, children are diagnosed within the first two years of life. A mother may, for example, be alerted that her toddler has a problem when he begins crawling into objects, rather than around them.

Long-term survivors of retinoblastoma who have received radiation therapy at an early age develop a typical deformity of their facial bones and soft tissues (midfacial hypoplasia). There is also loss of vision, due either to loss of one eye or varying degrees of decrease in visual acuity, caused by the tumor or treatment.

In the initial phase of a research study carried out in collaboration with Dr. Naomi Weintraub from the School of Occupational Therapy and Prof. Jacob Pe'er, Chairman of the Department of Ophthalmology, the team conducted a comprehensive assessment of the quality of life in a group of children cured of retinoblastoma. After investigating their physical, emotional, social, and academic well-being, they found that these children had lower self-esteem and poorer emotional health as judged by their parents, as well as a lower quality of life at school.

The second phase of the study is currently assessing body image and vision-related deficits in motor function and coordination. Since patients with retinoblastoma often undergo removal of the affected eye, even though the child is cured of the cancer, the impact appears to be significant on the young patients' self-perception, with social and interpersonal adverse consequences. At the same time, the cancer survivors may experience vision-related impairments in motor function and coordination since removal of the eye puts them at risk for impairments in this domain.

Once all the data is analyzed, Hadassah will design the comprehensive intervention program that will address these deficits in quality of life, body image, and vision-related motor function and coordination.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More